Relay Therapeutics (RLAY) Expected to Post Earnings on Thursday

Relay Therapeutics (NASDAQ:RLAY) is expected to be releasing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Relay Therapeutics to announce earnings of ($0.3911) per share and revenue of $0.96 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:00 PM ET.

Relay Therapeutics (NASDAQ:RLAY) last issued its earnings results on Tuesday, May 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The business had revenue of $3.00 million for the quarter, compared to the consensus estimate of $5.58 million. On average, analysts expect Relay Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Relay Therapeutics Price Performance

Relay Therapeutics stock opened at $18.78 on Tuesday. The company’s 50 day simple moving average is $17.27 and its 200 day simple moving average is $13.19. Relay Therapeutics has a fifty-two week low of $3.03 and a fifty-two week high of $20.79. The firm has a market capitalization of $3.60 billion, a price-to-earnings ratio of -11.96 and a beta of 1.69.

Insider Buying and Selling at Relay Therapeutics

In related news, insider Peter Rahmer sold 50,000 shares of the firm’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $19.09, for a total value of $954,500.00. Following the completion of the transaction, the insider owned 225,857 shares of the company’s stock, valued at approximately $4,311,610.13. This trade represents a 18.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Thomas Catinazzo sold 1,459 shares of Relay Therapeutics stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $18.61, for a total transaction of $27,151.99. Following the completion of the sale, the chief financial officer owned 158,285 shares in the company, valued at $2,945,683.85. The trade was a 0.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 427,356 shares of company stock valued at $7,461,240 over the last ninety days. 5.04% of the stock is currently owned by company insiders.

Institutional Trading of Relay Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of RLAY. Commodore Capital LP bought a new stake in Relay Therapeutics in the second quarter valued at approximately $46,191,000. Bellevue Group AG boosted its stake in shares of Relay Therapeutics by 1.4% during the 3rd quarter. Bellevue Group AG now owns 8,345,610 shares of the company’s stock worth $43,564,000 after acquiring an additional 114,740 shares during the period. State Street Corp boosted its stake in shares of Relay Therapeutics by 26.8% during the 4th quarter. State Street Corp now owns 6,426,111 shares of the company’s stock worth $54,365,000 after acquiring an additional 1,360,121 shares during the period. Geode Capital Management LLC increased its holdings in shares of Relay Therapeutics by 11.6% during the 4th quarter. Geode Capital Management LLC now owns 3,409,363 shares of the company’s stock worth $28,849,000 after acquiring an additional 354,777 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Relay Therapeutics by 14.6% during the 1st quarter. Millennium Management LLC now owns 2,942,875 shares of the company’s stock worth $7,710,000 after acquiring an additional 374,491 shares during the last quarter. Institutional investors and hedge funds own 96.98% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on RLAY shares. JPMorgan Chase & Co. initiated coverage on shares of Relay Therapeutics in a report on Wednesday, July 8th. They issued an “overweight” rating and a $28.00 price target for the company. Citigroup reiterated an “outperform” rating on shares of Relay Therapeutics in a report on Wednesday, May 20th. The Goldman Sachs Group increased their price target on Relay Therapeutics from $22.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Barclays raised their price target on Relay Therapeutics from $21.00 to $27.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. Finally, Zacks Research lowered Relay Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 22nd. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $24.92.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.